Ready to eat: Investors fork out $76M for Pheast’s cancer therapiesnews2022-04-25T22:59:57+00:00April 25th, 2022|FierceBiotech|
Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration endsnews2022-04-25T21:22:15+00:00April 25th, 2022|FierceBiotech|
UPDATE: Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration endsnews2022-04-25T21:22:15+00:00April 25th, 2022|FierceBiotech|
Trevena’s COVID-19 drug trial halted for inferiority, as NIH continues ACTIV house cleaningnews2022-04-25T19:53:33+00:00April 25th, 2022|FierceBiotech|
UPDATE: Trevena’s COVID-19 drug trial halted for inferiority as NIH continues ACTIV house cleaningnews2022-04-25T19:53:33+00:00April 25th, 2022|FierceBiotech|
Progress with Promise with Ibex® Design’s 11-month DNA to IND guaranteenews2022-04-25T19:26:16+00:00April 25th, 2022|FierceBiotech|
Another setback for Axsome as migraine med expected to get a no from FDAnews2022-04-25T17:33:36+00:00April 25th, 2022|FierceBiotech|
Vivo Capital seeds new venture with $60M to take Arrowhead therapies to Chinanews2022-04-25T16:29:05+00:00April 25th, 2022|FierceBiotech|
Roche delays DMD drug deadline, decides to rejig MS trials because of Ukraine warnews2022-04-25T14:45:52+00:00April 25th, 2022|FierceBiotech|
Black Diamond runs into rocky terrain, trims 30% of workforce and cuts precision oncology programnews2022-04-25T14:40:43+00:00April 25th, 2022|FierceBiotech|
